The $180 a share offer represents a 29% premium on Kite's share price, a level of extra expenditure which had become common in pharma buy-outs in recent years. However the pharma M&A market has ...

Kite's most advanced TCR therapy is KITE-439, for solid tumours associated with human papillomavirus (HPV) type 16, including cervical, head and neck, anal and genital cancers.